You are not logged in.

Recent advances in anti-survivin treatments for cancer

Kanwar, Rupinder K., Cheung, C. H., Chang, J. Y. and Kanwar, Jagat R. 2010, Recent advances in anti-survivin treatments for cancer, Current medicinal chemistry, vol. 17, no. 15, pp. 1509-1515, doi: 10.2174/092986710790979935.

Attached Files
Name Description MIMEType Size Downloads

Title Recent advances in anti-survivin treatments for cancer
Author(s) Kanwar, Rupinder K.
Cheung, C. H.
Chang, J. Y.
Kanwar, Jagat R.ORCID iD for Kanwar, Jagat R.
Journal name Current medicinal chemistry
Volume number 17
Issue number 15
Start page 1509
End page 1515
Total pages 7
Publisher Bentham Science Publishers
Place of publication Hilversum, The Netherlands
Publication date 2010-05-01
ISSN 0929-8673
Keyword(s) Survivin
Survivin antagonists
Summary Apoptosis occurs via extrinsic or intrinsic signalling each triggered and regulated by many different molecular pathways. In recent years, the selective induction of apoptosis through survivin in tumour cells has been increasingly recognized as a promising approach for cancer therapy. Survivin has multiple functions including cytoprotection, inhibition of cell death, and cell-cycle regulation, especially at the mitotic process stage, all of which favour cancer survival. Many studies on clinical specimens have shown that survivin over expression is invariably up regulated in human cancers, associated with resistance to chemotherapy or radiation therapy, and linked to poor prognosis, suggesting that cancer cells survive with survivin. On the basis of these findings, survivin has been proposed as an attractive target for new anticancer interventions. Survivin inhibitors recently entered clinical trials. Recent studies suggest a possible role for survivin in regulating the function of normal adult cells. However, the expression and function of survivin in normal tissues are still not well characterized and understood. Still better understandings of survivin's role in tumour versus normal cells are needed for designing the strategies to selectively disrupt survivin in cancers. In the present review, we summarise the importance of recent survivin-targeted cancer therapy for future clinical application.
Language eng
DOI 10.2174/092986710790979935
Field of Research 111716 Preventive Medicine
Socio Economic Objective 920412 Preventive Medicine
HERDC Research category C1 Refereed article in a scholarly journal
Persistent URL

Document type: Journal Article
Collection: Centre for Biotechnology and Interdisciplinary Sciences (BioDeakin)
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 58 times in TR Web of Science
Scopus Citation Count Cited 66 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 534 Abstract Views, 6 File Downloads  -  Detailed Statistics
Created: Thu, 16 Dec 2010, 13:15:53 EST by Kislay Roy

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact